Anaphylaxis Clinical Trial
— PEAAPOfficial title:
PEAnut Anaphylaxis Predictors
Verified date | January 2020 |
Source | John Hunter Children's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Peanut allergy can be life-threatening. Current diagnostic techniques for peanut allergy have high sensitivity, but not high specificity. This clinical trial will test the validity of a novel blood biomarker (compared with current testing) as a diagnostic predictor of anaphylaxis to peanut.
Status | Completed |
Enrollment | 40 |
Est. completion date | December 2019 |
Est. primary completion date | August 28, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 17 Years |
Eligibility |
Inclusion Criteria: - Children aged 2 - 17 years with an allergy to peanut and require peanut challenge to confirm peanut allergy. Exclusion Criteria: - Children with Peanut Skin Prick Test (SPT) wheal size greater than 10mm as these children are likely to have clinical peanut allergy (no clinical indication for food challenge). |
Country | Name | City | State |
---|---|---|---|
Australia | John Hunter Children's Hospital | New Lambton | New South Wales |
Lead Sponsor | Collaborator |
---|---|
John Hunter Children's Hospital | Aerocrine AB, Hunter Childrens Research Foundation, Australia, Hunter Medical Research Institute, Australia, Thrasher Research Fund, University of Newcastle, Australia |
Australia,
American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30. — View Citation
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. — View Citation
Sampson HA, Gerth van Wijk R, Bindslev-Jensen C, Sicherer S, Teuber SS, Burks AW, Dubois AE, Beyer K, Eigenmann PA, Spergel JM, Werfel T, Chinchilli VM. Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report. J Allergy Clin Immunol. 2012 Dec;130(6):1260-74. doi: 10.1016/j.jaci.2012.10.017. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Blood biomarker predicting anaphylaxis at peanut food challenge | The primary outcome of the project is to confirm that a novel blood biomarker has a higher diagnostic accuracy as compared to current best testing in predicting anaphylaxis at open label peanut challenge. | At completion of peanut food challenge | |
Secondary | Blood biomarker in combination with FeNO, and/or Ara h2 sIgE predicting anaphylaxis at peanut food challenge | The secondary outcome will be to determine the value of the biomarker, FeNO and Ara h2 sIgE (individually and in combination) at predicting anaphylaxis or clinical allergy at open label peanut challenge. | At completion of peanut food challenge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04475003 -
Health Literacy Among Caregivers of Children With IgE-mediated Allergy With Risk of Anaphylaxis
|
||
Recruiting |
NCT04615065 -
Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
|
||
Recruiting |
NCT06065137 -
Standardised Drug Provocation Testing in Perioperative Hypersensitivity
|
N/A | |
Completed |
NCT00047918 -
Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing
|
N/A | |
Active, not recruiting |
NCT03953482 -
Evaluation of Medical Care and Patient's Knowledge About the Behavior to Take on Secondary Prevention of Anaphylaxis
|
||
Recruiting |
NCT05112367 -
Epidemiology and Management of Pediatric Anaphylaxis and Allergy in the Pediatric Emergency Department of Montpellier
|
||
Completed |
NCT03366298 -
Pharmacokinetics of Intramuscular Adrenaline in Food--Allergic Teenagers
|
Phase 4 | |
Completed |
NCT02958605 -
Smartphone Apps for Pediatric Resuscitation
|
N/A | |
Completed |
NCT04696822 -
Bioavailability of Nasal Epinephrine
|
Phase 1 | |
Completed |
NCT03942692 -
What is the Allergy Follow-up for Children After Anaphylactic Reaction? AFCAR : Allergy Follow-up for Children After Anaphylactic Reaction
|
||
Completed |
NCT02854969 -
Satisfaction of Patient With Anaphylaxis in the Use of a Medical Device
|
N/A | |
Completed |
NCT03282929 -
Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)
|
Phase 1 | |
Recruiting |
NCT01326741 -
Clonal Mast Cell Disorders in Exercise-Induced Anaphylaxis
|
N/A | |
Recruiting |
NCT06445374 -
Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing Immunotherapy or Oral Challenges
|
Phase 1 | |
Completed |
NCT01217138 -
Make up for the Epinephrine Autoinjector
|
Phase 4 | |
Completed |
NCT01432522 -
A Study for Absorption of Intranasal Epinephrine Compared to Conventional Intramuscular Epinephrine
|
N/A | |
Completed |
NCT02028065 -
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
|
Phase 1 | |
Active, not recruiting |
NCT01247415 -
Clinical Investigation on Allergic-like Reactions and Oculo-respiratory Syndrome After the H1N1 Pandemic Vaccine
|
N/A | |
Completed |
NCT00868842 -
Desensitization of Human Mast Cells: Mechanisms and Potential Utility for Preventing Anaphylaxis
|
N/A | |
Completed |
NCT04290507 -
Epidemiology and Outcome of Anaphylactic Shocks Admitted to Intensive Care Unit
|